What records are connected here?
- Evidence lanes
- 3
- Source years
- 13
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved2,3Evidence: Limited human dataHormones · Sexual and reproductive health
Also called Factrel, Lutrepulse, Gonadorelin acetate, Gonadorelin hydrochloride1,2,3
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), the ten-amino-acid hormone that FDA’s substance registry also records as luteinizing hormone-releasing hormone.1 FDA approved two gonadorelin drugs, Factrel in 1982 and Lutrepulse in 1989, but Drugs@FDA lists every product under both applications as discontinued.2,3 In a 1990 multicenter study of 109 women with hypothalamic amenorrhea, Lutrepulse led to ovulation in more than 90%. Gonadorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.4,7
| What it is | A synthetic decapeptide identical to gonadotropin-releasing hormone (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2), according to FDA’s substance registry.1 |
|---|---|
| FDA status | FDA-approved, but discontinued. Drugs@FDA lists Factrel, NDA 018123, approved September 30, 1982, and Lutrepulse, NDA 019687, approved October 10, 1989, and lists all of their products as discontinued.2,3 |
| Human evidence | A 1990 multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea, without a comparison group.4 |
| Evidence strength | Limited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned |
Gonadorelin is a synthetic peptide of ten amino acids with the same sequence as natural gonadotropin-releasing hormone. FDA’s substance registry also records it as luteinizing hormone-releasing hormone and as its acetate and hydrochloride salts.1
In the United States it was the active ingredient of Factrel, as gonadorelin hydrochloride, and of Lutrepulse, as gonadorelin acetate, according to Drugs@FDA.2,3
FDA’s substance registry records gonadorelin as an agonist of the gonadotropin-releasing hormone receptor.1
Lutrepulse was meant to restore normal ovulation in women whose own release of this hormone is reduced or absent, according to the 1990 study.4
In a 1990 multicenter study, 109 women with primary or secondary hypothalamic amenorrhea received Lutrepulse; 91% and 96% of them ovulated. Of pregnancies, 12% were multiple, and one woman who also took clomiphene had ovarian hyperstimulation.4
The authors judged it at least comparable in effectiveness to human menopausal gonadotropins, with lower overall risk, but the study had no randomized comparison group.4
Evidence-strength label: Limited human data. How this label is assigned
Yes, but Drugs@FDA lists the products under both of its applications as discontinued: Factrel (gonadorelin hydrochloride), NDA 018123, with an original approval date of September 30, 1982, and Lutrepulse (gonadorelin acetate), NDA 019687, with an original approval date of October 10, 1989.2,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list gonadorelin.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Gonadorelin is not among them.6,7
Why the products were discontinued: Drugs@FDA lists their status but the records reviewed here give no reason.2,3
How it compares with other fertility treatments in randomized trials, which the 1990 study did not run.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Gonadorelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Gonadorelin are a bounded selection, not every registration or paper about Gonadorelin. For the years before Gonadorelin was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Gonadorelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Gonadorelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Factrel and Lutrepulse; discontinued. A 1990 multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea reported ovulation in more than 90%. Gonadorelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Factrel and Lutrepulse; discontinued. A 1990 multicenter study of Lutrepulse in 109 women with hypothalamic amenorrhea reported ovulation in more than 90%. Gonadorelin is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date July 10, 2026
ClinicalTrials.gov record NCT04037254↗Added to PeptideScanner November 16, 2026Regulatory · added November 17, 2026
Drugs@FDA application NDA018123↗Source date September 30, 1982Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT04037254↗Source date July 10, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT02653092↗Source date March 2, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
5 of 5 selected trial records include at least one phase value; 5 of 5 include a status value in the retained structured contract.
16 of 16 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
The official Drugs@FDA dataset lists original submission 1 for NDA 018123 with status AP dated 1982-09-30, and names gonadorelin hydrochloride among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00000325 at 2026-11-16T17:31:07.936Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was gonadorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00296465 at 2026-11-16T17:31:07.936Z. Its registry update date was 2011-05-19, and PeptideScanner's reviewed identity mapping was gonadorelin.
16 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
Selected records span September 30, 1982 to July 10, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04037254 at 2026-11-16T17:31:07.936Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was gonadorelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02653092 at 2026-11-16T17:31:07.936Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was gonadorelin.↗
Literature metadata
PubMed lists PMID 36858006 in Journal of pharmaceutical and biomedical analysis as Case Reports, Journal Article, Review, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 32599272 in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V as Journal Article, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01976728 at 2026-11-16T17:31:07.936Z. Its registry update date was 2021-03-03, and PeptideScanner's reviewed identity mapping was gonadorelin.↗
Literature metadata
PubMed lists PMID 31731249 in Domestic animal endocrinology as Journal Article, with publication-date metadata of 2019-09-06 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 6353073 in Journal of pharmacological methods as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 1983-06 (month precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 30050082 in Scientific reports as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2018-07-26 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 6752326 in The Journal of endocrinology as Comparative Study, Journal Article, with publication-date metadata of 1982-10 (month precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 8491839 in Journal of chromatography as Comparative Study, Journal Article, with publication-date metadata of 1993-04-23 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00000325 at 2026-11-16T17:31:07.936Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was gonadorelin.↗
Literature metadata
PubMed lists PMID 2940565 in Presse medicale (Paris, France : 1983) as Case Reports, Letter, with publication-date metadata of 1986-05-10 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
American Journal of Obstetrics and Gynecology · Official source · Source checked November 16, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026